AstraZeneca (AZN)
(Delayed Data from NSDQ)
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$77.35 USD
+0.48 (0.62%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $72.07 in the latest trading session, marking a -0.37% move from the prior day.
AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica
by Zacks Equity Research
AbbVie (ABBV)/J&J's (JNJ) decision to withdraw the FDA's accelerated approval for Imbruvica in two blood cancer treatments is based on confirmatory studies data that do not support full approval.
UnitedHealth (UNH) to Post Q1 Earnings: What You Should Expect
by Zacks Equity Research
UnitedHealth's (UNH) first-quarter results are likely to reflect growing premiums and memberships.
The Zacks Analyst Blog Highlights J&J, AstraZeneca, Merck, Seagen and Pfizer
by Zacks Equity Research
J&J, AstraZeneca, Merck, Seagen and Pfizer are part of the Zacks Top Analyst Blog.
Pharma Stock Roundup: J&J's $8.9B Offer for Talc Litigation Settlement & Other Updates
by Kinjel Shah
J&J (JNJ) offers a $8.9 billion settlement to resolve its talc lawsuits. FDA approves Merck's (MRK) Keytruda plus Seagen's Padcev for a bladder cancer indication.
The Zacks Analyst Blog Highlights Mastercard, AstraZeneca, Philip Morris, TJX and Citigroup
by Zacks Equity Research
Mastercard, AstraZeneca, Philip Morris, TJX and Citigroup are included in this Analyst Blog.
Top Analyst Reports for Mastercard, AstraZeneca & Philip Morris
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AstraZeneca PLC (AZN) and Philip Morris International Inc. (PM).
AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal
by Zacks Equity Research
Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $70.25, moving +0.49% from the previous trading session.
Oncternal (ONCT) Down on Restructuring Plan to Extend Runway
by Zacks Equity Research
Oncternal (ONCT) closes the development program for zilovertamab to extend its cash runway into 2025. Shares are down on the same.
AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease
by Zacks Equity Research
CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.
This is Why Astrazeneca (AZN) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $68.64, marking a +0.06% move from the previous day.
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
by Zacks Equity Research
Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
by Zacks Equity Research
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $67.26, moving +1.04% from the previous trading session.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here's What is Driving Amgen (AMGN) Stock's Outperformance
by Zacks Equity Research
Amgen's (AMGN) key drugs like Prolia, Repatha and Otezla are driving sales. It is also rapidly advancing its robust pipeline.
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023?
by Zacks Equity Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments should keep Merck's (MRK) stock afloat in 2023.
Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $65.61, marking a -0.56% move from the previous day.
Astrazeneca (AZN) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023?
by Zacks Equity Research
AstraZeneca (AZN) expects total revenues to increase in the low-to-mid single-digit percentage in 2023 at CER.
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $65.18, moving +1.54% from the previous trading session.
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
by Zacks Equity Research
Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.
Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi
by Zacks Equity Research
J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi have been highlighted in this Industry Outlook article.